Citation only
via Europe PMC
Osteoarthritis and dementia: contrasting disorders driven by mutual pathways of autophagy, mTOR, GLP-1, AMPK, Wnt, and WISP1.
Expert review of clinical pharmacology · 2026
Deregulated nutrient-sensing
Altered intercellular communication
Disabled macroautophagy
Rapamycin / mTOR inhibition
Human
Abstract
<h4>Introduction</h4>Increased global lifespan is paralleled by a rise in non-communicable diseases with osteoarthritis and dementia, including Alzheimer's disease, impacting all nations with severe disability, death, and financial burden.<h4>Areas covered</h4>Given that osteoarthritis and dementia are worsened with advancing age, progressive in nature, and presently remain only with symptomatic treatments, development of advanced comprehensive therapies is critical for these disorders. New innovative work offers insight into the underlying clinical bond between degenerative joint disease and cognitive loss. Data sources using systematic literature search employed PubMed, Scopus, Web of Science, and ScienceDirect from January 2021 through February 2026.<h4>Expert opinion</h4>Although affecting diverse organ systems, degenerative joint disease and dementia are intimately connected by shared cellular pathways responsible for disease onset and progression. Pioneering avenues of investigation of oxidative stress, autophagy(definition), the mechanistic target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR), cellular metabolism mechanisms with glucagon-like peptide-1 (GLP-1) receptors and AMP activated protein kinase (AMPK), Wnt signaling, and Wnt1 inducible signaling pathway protein 1 (WISP1) offer exciting treatment opportunities for osteoarthritis and Alzheimer's disease. Ultimately, these complex pathways will necessitate focus upon their intricate dependence that may benefit from several targeted approaches including artificial intelligence applications for fruitful clinical translation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1080/17512433.2026.2671269
- Canonical
- link ↗
- Fetched
- 2026-07-01 MST
Cite this
APA
K., M. (2026). Osteoarthritis and dementia: contrasting disorders driven by mutual pathways of autophagy, mTOR, GLP-1, AMPK, Wnt, and WISP1. <em>Expert review of clinical pharmacology</em>. https://doi.org/10.1080/17512433.2026.2671269
Vancouver
K. M. Osteoarthritis and dementia: contrasting disorders driven by mutual pathways of autophagy, mTOR, GLP-1, AMPK, Wnt, and WISP1. Expert review of clinical pharmacology. 2026. doi:10.1080/17512433.2026.2671269.
BibTeX
@article{maiese2026Osteoa,
title = {Osteoarthritis and dementia: contrasting disorders driven by mutual pathways of autophagy, mTOR, GLP-1, AMPK, Wnt, and WISP1.},
author = {Maiese K.},
journal = {Expert review of clinical pharmacology},
year = {2026},
doi = {10.1080/17512433.2026.2671269},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging advances 2026
Open access · OA
Dementia, mood disorders, and aging: Bridging new avenues of care through shared biological pathways.
Cells 2023
Open access · CC-BY
Cornerstone Cellular Pathways for Metabolic Disorders and Diabetes Mellitus: Non-Coding RNAs, Wnt Signaling, and AMPK
biorxiv 2025
Preprint · CC-BY
Long term improvement in Alzheimers Disease with Transcranial Direct Current Stimulation
Antioxidants (Basel, Switzerland) 2026
Open access · OA
Chasing the FoxO in Metabolic Disorders: Novel Considerations for Oxidative Stress, Programmed Cell Death, Wnt, and the Gut Microbiome.
PLoS ONE 2015
Open access · CC-BY
Correction: Drug Synergy Drives Conserved Pathways to Increase Fission Yeast Lifespan
Cell Death and Differentiation 2022
Open access · OA